Robson Dossa

Company: Arovella

Job title: Vice President

Seminars:

Invariant NKT Cells Unleashed: Building a Pipeline for Cutting-Edge Allogeneic Cell Therapies 11:30 am

• iNKT-CD19 CAR progressing from discovery towards first-in-human clinical trial against hematological malignancies. • Combining iNKT-CD19 CAR with a CD19-expressing oncolytic virus to target solid tumors. • Incorporation of CARs targeting solid tumors into the iNKT platform. Claudin 18.2 as a promising target against gastric and pancreatic tumors.Read more

day: Day Two